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Crotalus durissus terriﬁcus, C. d. collilineatus, C. d. cascavella and C. d. marajoensis are
responsible minor but severe snake bites in Brazil. The venoms of these snakes share the
presence of crotoxin, a neurotoxin comprising of two associated components, crotapotin
and phospholipase A2 (PLA2). Treatment of the victims with speciﬁc antiserum is the
unique effective therapeutic measure. The ability of anti-Crotalus antisera produced by the
routine using crude venom to immunize horses or puriﬁed crotoxin and PLA2 as individual
immunogens was compared. Antisera obtained from horses immunized with C. durissus
terriﬁcus crude venom were able to recognize and neutralize not only the toxins presents
in C. durissus terriﬁcus, but also the ones present in the venoms from C. d. collilineatus, C. d.
cascavella and C. d. marajoensis. Antisera from horses immunized with individual crotoxin
or PLA2, although in lesser titers, were also able of recognizing the toxins in all four
Crotalus species and neutralize the lethality of the C. d. terriﬁcus venom.
 2013 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Envenomation caused by Crotalus snake bites represents
6.2% of reported cases of envenomation in Brazil, with an
estimated mortality rate of 1.8% per year (Ministério da
Saúde, Brasil, 2001). As is shown in Fig. 1, ﬁve geographic
subspecies of Crotalus are found in Brazil. Crotalus durissus
terriﬁcus, although common in the southern states of São
Paulo, Minas Gerais, Paraná and Rio Grande do Sul, is also
present in the areas of Mato Grosso, Rondônia, Amazonas
and Pará to the west, including Paraguai, Uruguai and
Argentina. Crotalus durissus cascavella is found in the dry
“caatinga” region, ranging from southern Maranhão, Piauí,
Ceará and Rio Grande do Norte. Crotalus durissus collili-
neatus is present in central and northern Brazil, including
parts of Rondônia, Mato Grosso, Goiás, southWestern Bahia,uenf.br (W. Dias da
he quality of antisera
fe (in memoriam).
lsevier OA license.Western Minas Gerais, and São Paulo (where it in-
termingles with C. durissus terriﬁcus), and its presence may
extend southward into Western Paraná (Fig. 1). Crotalus
durissus marajoensis is restricted to the “cerrado” of Ilha de
Marajó in the state of Pará. Crotalus durissus ruruima is also
present in Roraima (Melgarejo, 2003). The general phar-
macological and composition of the venom from the vari-
ous Crotalus species in Brazil is very similar (Santoro et al.,
1999; Boldrini-Franca, 2010). The toxins in Crotalus venoms
are crotoxin, crotamin (Gonçalves, 1956) and gyroxin
(Barrio, 1961; Barrabin et al., 1978). Crotoxin is responsible
for both the neurotoxic and systemic myotoxic effects
characteristic of this venom. Crotoxin was ﬁrst isolated
from the venom of C. d. terriﬁcus (Slotta and Fraenkel-
Conrat, 1938). Crotoxin comprises two sub-units that are
non-covalently linked: the non-catalytic crotoxin A (CA), or
crotapotin, and the catalytic unit, crotoxin B (CB), which is
also known as PLA2. Crotapotin is an acidic polypeptide
with no detectable enzymatic activity (Harris, 1991). Cro-
tapotin, working as a chaperon, potentiates the toxicity of
PLA2 by about 35-fold. PLA2 is a basic single-chain poly-
peptide formed by 123 amino acid residues. PLA2 binds pre-
Fig. 1. Distribution of Crotalus subspecies in Brazil (modiﬁed from
Melgarejo, 2003).
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and Bon, 1982). Mice and horses immunized with puriﬁed
PLA2 are protected from the lethal effects of the C. d. terri-
ﬁcus crude venom (Dos Santos et al., 1988, 1989). While
antibodies speciﬁc to crotapotin are unable to neutralize
crotoxin activity, antibodies speciﬁc to PLA2 neutralize
crotoxin but do not cross-react with crotapotin (Choumet
et al., 1998).
Crotaminwas isolated as a basic protein, i.p.10.3, from C.
d. terriﬁcus (Gonçalves, 1956). The biological and bio-
chemical molecular features of crotamin suggest that cro-
tamin is related to myotoxins (Bieber and Nedelkov, 1997).
Crotamin was puriﬁed (Seki et al., 1980), and its nucleotide
sequence was determined (Rádis-Baptista et al., 1999).
In vitro and in vivo studies indicate that crotamin is a cell
membrane-penetrating protein with nuclear localization.
Although the nature of the interaction between crotamin
and cells has not been investigated at the molecular level,
the suggested mechanisms differ from those of DAPI or 5-
BrdU. Cumulatively, the data indicate that crotamin could
be a marker for actively proliferating cells (Kerkis et al.,
2004).
Gyroxin was described by Barrio (1961), and it was
subsequently isolated from the venom of C. d. terriﬁcus
(Barrabin et al., 1978). This toxin was ﬁrst identiﬁed by its
ability to induce a loss of equilibrium and the subsequent
complete revolutions of the body around the longitudinal
axis upon experimental injection into mice (barrel roll).
These manifestations are preceded by systemic skeletal
muscle contractions (Kosako et al., 2000). In addition to
these typical neurological toxic effects, gyroxin exhibits
a thrombin-like activity ﬁbrinogen A cleavage at its N-ter-
minal peptide region (Raw et al., 1986).
Victims of C. d. terriﬁcus exposure exhibit almost no local
symptoms but do present grave neurotoxic and myotoxic
symptoms (Azevedo-Marques et al., 2003). The neurotoxic
effects include eyelid heaviness; facial muscle paralysis,
speciﬁcally around the mouth; blurred vision; ptosis;
external ophthalmoplegia; and progressive respiratory
muscle paralysis. The myotoxic effects include diffusemuscular pain, red or brown urine, decreased blood coag-
ulation, and increased serum levels of creatine kinase (CK),
lactic dehydrogenase (LDH), aminotransferase aspartase
(AST) and aldolase. Acute renal failure (ARF) is the most
important systemic symptom. Histopathological analyses
of muscle fragments collected distal from the bite location
show myonecrosis with lysis of the myoﬁlaments. The in-
duction of myonecrosis by C. d. terriﬁcus venom has been
experimentally conﬁrmed, and this effect was demon-
strated to be caused by the sub-units of crotoxin
(Kouyoumdjian et al., 1986). Neurotoxicity (Vital Brazil,
1966), nephrotoxicity (Hadler and Vital Brazil, 1966),
myotoxicity (Breithaupt, 1976) and cardiotoxicity (Santos
et al., 1990) have been also ascribed to crotoxin. The vari-
ety of local and systemic effects resulting from Crotalus
venom injection is likely the result of the combined action
of the toxic components of the venom.
Current antiserum production still relies on the use of
whole snake venom as an immunogen. This strategy results
in the production of antibodies against both the toxic and
non-toxic components of the venom, resulting in an anti-
serum that contains both relevant and non-relevant ther-
apeutic antibodies. The injection of irrelevant antibodies
into victims of snake bites can increase the risk adverse
reactions (Cardoso et al., 1993). Thus, using puriﬁed toxic
venom components instead of whole venom during anti-
serum production is the ﬁrst step to obtainingmore speciﬁc
antivenoms. To promote the selection and expansion of
high-afﬁnity naïve and memory lymphocyte subsets, the
immunization period and the amount of injected immu-
nogen should be reduced. Steiner and Eisen (1966) dem-
onstrated that smaller quantities of antigen result in
antibodies with high titers and higher afﬁnity. Highly
speciﬁc antivenom antibodies exhibiting high avidity and
high-afﬁnity will likely result in more efﬁcient and reliable
therapeutic tools.
This work aims to compare the quality between sera
produced by injecting crude Crotalus venom into horses
and antivenoms produced using puriﬁed crotoxin and
phospholipase A2 as immunogens. Evaluated parameters
include the antibody titers against whole venom and the
toxic components of venom, the levels of neutralizing an-
tibodies, the antibody afﬁnity and the ability of these an-
tibodies to cross-react with venoms from related Crotalus
subspecies found in Brazil.
2. Materials and methods
2.1. Reagents
Tris buffer (Tris HCl, 25 mM; pH 7.4), complete MMT80
(Marcol Montanide ISA 50, 2 mL; sodium chloride 0.15 M,
5 mL; Tween 80, 1 mL; lyophilized BCG, 1 mg), incomplete
MMT80 (Marcol Montanide ISA 50, 2 mL; sodium chloride
0.15 M, 5 mL; Tween 80, 1 mL), solution A for SDS buffer
(Tris, 6.25 mM; SDS, 6.94 mM; pH 6.8); SDS buffer for
reduction conditions (solution A, 8.5 mL; glycerol, 1 mL; b-
mercaptoethanol, 0.5 mL; bromophenol blue 1%, 2 mL), PBS
buffer (potassium chloride, 2.6 mM; monobasic potassium
phosphate, 1.5 mM; sodium chloride, 76 mM; disodium
phosphate, 8.2 mM; pH 7.2–7.4), AP buffer (Tris HCl,
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5 mM; pH 9.5), NBT solution (NBT, 50 mg; dimethyl-
phormamide, 700 mL; H2O, 300 mL), BCIP solution (BCIP,
50 mg; dimethylphormamide, 1 mL), developing solution
for Western/dot blotting (AP buffer, 5 mL; NBT solution,
33 mL; BCIP solution, 16.5 mL), citrate buffer (citric acid,
0.1 M; monobasic sodium phosphate, 0.2 M; pH 5.0), OPD
solution (OPD, 20 mg; citric acid, 1 mL), and substrate
buffer for ELISA (citrate buffer, 5 mL; OPD solution, 100 mL;
H2O2 30 volumes, 5 mL). All the reagents used were
obtained from Sigma–Aldrich (USA), except from NBT/BCIP,
obtained from Molecular Probes (USA).
2.2. Quantiﬁcation of proteins
The protein concentration of the venoms and sera was
assessed by the bicinchoninic acid method (Smith et al.,
1985) with the Pierce BCA Protein Assay Kit (Rockford, IL).
2.3. Venoms
C. d. terriﬁcus, C. d. collilineatus, C. d. cascavella and C. d.
marajoensis venoms were supplied by “Laboratório de
Venenos, Instituto Butantan”. Each venom batch was a mix-
ture of samples collected from several snake specimens and
lyophilized. The lethality (LD50) of crude Crotalus spp.
Venoms was determined by intraperitoneally injecting
male Swiss mice, 18–20 g, with 500 mL of PBS containing
1.0, 2.0, 4.0 or 8.0 mg of the venoms. Fourmicewere used for
each venom dose. The deaths were recorded after 48 h, and
the death/survival ratio was determined by probit analysis
(Finney, 1992; World Health Organization, 1981).
2.4. Isolation of crotoxin and phospholipase A2 from C. d.
terriﬁcus venom
Samples of C. d. terriﬁcus venom (20.0 mg) were applied
to a column packed with Mono Q HR 5/5 resin (Amershan
Pharmacia Biotech AB/USA), which was previously equili-
brated at room temperature with 25 mM Tris, pH 7.4 buffer.
After washing the column with the same buffer, a linear
gradient of NaCl starting from 0 to 0.1 Mwas applied under
a 30 ml/h ﬂow, and fractions corresponding to each protein
peak were collected. Protein concentration and PLA2 ac-
tivity in each protein peak were determined using the
method described by Price (2007). The absorbance at
280 nm was determined on UPC-900 (ÄKTA FPLC) and by
speciﬁc hydrolysis of the PLA2 substrate L-Phosphati-
dylcholine, Type X-E, minimum 60% TLC (Sigma–Aldrich,
Inc., 3050 Spruce Street, St. Louis, MO 63103 USA). Fractions
exhibiting PLA2 activity were pooled together, lyophilized
and stored until immunization of the horses.
2.5. Animals
Groups of 20 adult horses (400–450 kg) are regularly
used to produce anti-Crotalus antivenom. Six horses (two
per group) were selected to be immunized with C. d. ter-
riﬁcus venom, puriﬁed crotoxin or PLA2 venom compo-
nents. The animals, not previously immunized, were
maintained in a special animal house at the São JoaquimFarm, Instituto Butantan, São Paulo, Brazil. Before immu-
nization, the animals were vaccinated against the most
common equine infectious diseases. Male Swiss out bred
mice, 18–20 g, (four per group) were used in protocols to
determine the lethality (LD50) of the venoms and the
neutralizing potency (ED50) of the antivenoms. Mice were
kept in standard conditions, with light between 7:00 a.m.
and 6:00 p.m., a temperature of 22  2 C and laboratory
food and water ad libitum. All animals used in this study
were maintained and treated under strict ethical condi-
tions in accordance with the “International Animal Welfare
recommendations” (Remfry, 1987) and the “Committee
Members, International Society on Toxinology” (1992). This
project was approved by the Ethics Committee of Animal
Usage in Research (Protocol No: 790/11) of the Instituto
Butantan.
2.6. Antigen preparation and immunization schedule
Horses selected to produce regular antivenom received
four inoculations of a mixture containing equal amounts of
C. d. terriﬁcus and C. d. collilineatus venoms. Horses were
immunized as described in Guidolin et al. (2010). Horses
were s.c. injected in the back with 2.0 mL of incomplete
MMT80 or complete MMT80 adjuvant mixtures, or with
0.15 M NaCl containing 2.5–5.0 mg of venom. Two vacci-
nations were performed, with two weeks between the
vaccinations. Two weeks after the last immunization, the
antisera antibody titers were evaluated: the horses were
bled, and a volume of blood corresponding to one-twelfth
of each animal’s body weight was collected in a sterile
plastic bag containing anticoagulant. Plasma and cells were
separated by gravity sedimentation, and the cells were re-
infused into the corresponding horse through the jugular
vein. Plasma from the same horse was pooled and stored at
4 C. Before immunization, blood samples were drawn by
jugular vein puncture, and serawas stored at20 C for use
as negative controls in the antisera antibody de-
terminations. Three months after bleeding, boosters with
similar doses of venom in PBS were given, and blood was
collected and processed as described previously (Guidolin
et al., 2010). This ﬁnal procedure was generally repeated
for the following two years.
Horses included in the Experimental Groups received
four inoculations of the following mixtures. Experimental
Group 1 (n ¼ 2): 500 mg/animal of crude C. d. terriﬁcus
venom; Experimental Group 2 (n ¼ 2): 200 mg/animal of
partially puriﬁed crotoxin; and Experimental Group 3
(n ¼ 2): 100 mg/animal of partially puriﬁed PLA2. The ﬁrst
inoculation of every group was prepared in Complete
MMT80 and the respective antigens. The second inocu-
lation was prepared in Incomplete MMT80 and the
respective antigens. The ﬁnal two inoculations were pre-
pared in 8.0 mL of 0.15 M NaCl containing the respective
antigens. The inoculations were performed 15 days apart by
subcutaneous injection at four different points of the dorsal
region of each animal. Fifteen days after the last inocu-
lation, blood was collected in sterile plastic bags containing
anticoagulant solution (citric acid, 1.47 g; sodium citrate,
4.80 g; dextrose, 1.47 g; dissolved in a sufﬁcient amount of
distilled water to a ﬁnal volume of 100mL) by venipuncture
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night in a refrigerating chamber (4–8 C). Plasma samples
from each horse were pooled and stored at 20 C. Blood
cells resulting from the bleeding were re-infused in the
original horse.
2.7. Antivenoms
Four equine plasma samples (Batches No: #143, #158,
#223 and #356) and six F(ab0)2 anti-Crotalus commercial
antivenom preparations (Batch #1006140; Batch
#100107119; Batch #1007187; Batch #1009230; Batch
#1010282; Batch #1010283) were provided by “Divisão de
Desenvolvimento Tecnológico e Produção – Seção de Proc-
essamento de Plasmas Hiperimunes, Instituto Butantan”.
Experimental plasma was obtained by separating plasma
from the blood collected from the experimental animals, as
described in Section 2.7.
2.8. Processing the horse plasma
The procedure presently used to manufacture horse
commercial serum from plasma is completely enclosed and
automated (Raw et al., 1996). The procedure used in this
study, improved with the introduction of additional ﬁltra-
tion and chromatography, included ten steps (Guidolin
et al., 2010). Before the antivenom was released to treat
envenomed victims, the puriﬁed F(ab0)2 were submitted to
a quality control evaluation in order to verify the absence of
bacterial contamination, bacterial lipopolysaccharide and
toxic substances. The ﬁnal products were adjusted to con-
tain the desired neutralizing antibody titer in less than
10 mg of protein/ml and were labeled as “Crotalic Anti-
serum”. One milliliter of the preparation neutralized 1.5 mg
of Crotalus venom. Each ampoule contained 10 ml of anti-
venom. This antivenom, as well as the other antivenoms
produced by the “Divisão de Desenvolvimento Tecnológico e
Produção – Instituto Butantan”, was prepared according to
the recommendations of the World Health Organization
(1981). Serum rich in F(ab0)2 fragments was produced as
described by Towbin et al. (1979).
2.9. SDS-PAGE and Western blot analyses
Western blot analysis was carried out according to the
method previously described by Towbin et al. (1979). Crude
C. d. terriﬁcus, C. d. collilineatus, C. d. cascavella and C. d.
marajoensis venoms (10 mg) and partially puriﬁed crotoxin
and PLA2 (2 mg) were treated with SDS-PAGE sample buffer
under reducing conditions and resolved in a 12.5% poly-
acrylamide gel. Some preparations were stained with silver
sulfate, while others were electroblotted onto nitro-
cellulose membranes, according the method described by
Laemmli (1970). These membranes were blocked with PBS
buffer containing 5% BSA at 37 C for 2 h, washed with PBS,
and treated with equine anti-Crotalus antivenoms diluted
to 1:5000 in PBS plus 0.1% BSA for 1 h at room temperature
on a horizontal shaker. After being washed three times
with PBS plus 0.05% Tween-20, the membranes were
incubated with rabbit anti-horse IgG conjugated to alkaline
phosphatase (whole molecule) diluted 1:7500 in PBS plus0.1% BSA and 0.05% Tween-20. Then, the membranes were
incubated for 1 h at room temperature on a horizontal
shaker. The membranes were washed three times with PBS
plus 0.05% Tween-20 and placed in developing solution for
Western blotting. The reaction was terminated by washing
with distilled water.
2.10. Quantiﬁcation of the antivenom antibodies
Polystyrene, high-afﬁnity ELISA plates (96 wells) were
coated with 1.0 mg of crude C. d. terriﬁcus, C. d. collilineatus,
C. d. cascavella or C. d. marajoensis venom in 100 mL of PBS
buffer and kept overnight at 4 C. In some assays, crotoxin
or PLA2 puriﬁed from C. d. terriﬁcus was used as the an-
tigen. The wells were blocked for 2 h at 37 C with 200 mL
of PBS plus 5% BSA. The wells were washed with 200 uL of
PBS. Serial dilutions of horse IgG or F(ab0)2 preparations
(1:4000 to 2,048,000) in PBS plus 0.1% BSA were prepared,
and 100 mL of each dilution was added to individual wells.
The plates were then incubated at 37 C for 1 h, and then,
the wells were washed three times with the wash buffer.
Rabbit peroxidase-conjugated anti-horse IgG (whole
molecule) (Sigma Aldrich, St. Louis, MO) diluted (1:20,000)
in PBS plus 0.1% BSA and 0.05% Tween-20 (100 mL/well)
was added to the plates. The plates were incubated for 1 h
at 37 C. After three washes with the wash buffer, 50 mL of
substrate buffer were added to each well, and plates were
incubated at room temperature for 15 min. The reaction
was terminated with 50 mL of 4 N sulfuric acid per well.
Absorbance was recorded at 492 nm using an ELISA plate
reader (Labsystems Multiskan Ex, Thermo Fisher Scientiﬁc
Inc., Walthan, MA). IgG from horses collected before im-
munization was always used as a negative control. The IgG
dilution giving an optical density of 0.2 was used to cal-
culate the U-ELISA per milliliter of the undiluted IgG so-
lution. One U-ELISA was deﬁned as the smallest dilution of
antibody that presented an O.D. of 0.2 under conditions of
the ELISA assay, as described previously (Almeida et al.,
2008). The value was then multiplied by 10 to corre-
spond to milliliters.
2.11. Antivenom afﬁnity measurement
The afﬁnity of anti-Crotalus antibody was measured by
ELISA, as described above, with the inclusion of a potassium
thiocyanate (KSCN) elution step (Pullen et al., 1986;
Romero-Steiner et al., 2005). After the serum incubation
step, dilutions of KSCN (0.0–5.0 M, in intervals of 0.50 M) in
PBS were added to the wells and incubated for 30 min at
room temperature. The remaining bound antibodies were
detected with rabbit peroxidase-conjugated anti-horse IgG
(whole molecule) (Sigma Aldrich, St. Louis, MO) diluted
(1:20,000) in PBS plus 0.1% BSA (100 mL/well). After three
washes with the wash buffer, 50 mL/well of substrate buffer
was added, and the plates were incubated at room tem-
perature for 15 min. The reaction was terminated with
50 mL/well of 4 N sulfuric acid. Absorbance was recorded at
492 nm using an ELISA plate reader (Labsystems Multiskan
Ex, Thermo Fisher Scientiﬁc Inc., Walthan, MA). The results
are expressed as follows: afﬁnity index (AI) ¼ M KSCN
needed to displace 50% of the bound antibodies.
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A ﬁxed amount of 5 LD50 of C. d. terriﬁcus venom and
various dilutions of antivenoms were incubated for 30 min
at 37 C. Venom samples incubated only with PBS buffer
were used as controls. After incubation, 500 mL aliquots of
the mixtures were intraperitoneally injected in the mice.
Five mice were used per mixture. The death/survival ratio
was recorded 48 h after the injection. ED50 was estimated
by probit analysis (Finney, 1992).
2.13. Statistical analysis
The obtained data were subject to a one-way ANOVA,
followed by the Dunn’s multiple comparison test. Differ-
ences were considered to be signiﬁcant for P < 0.05.
3. Results
3.1. General characteristics of Crotalus venom
The protein concentrations (mg/mL) and lethality (LD50)
of the C. d. terriﬁcus, C. d. collilineatus, C. d. cascavella and C.
d. marajoensis venoms used in this work were determined
by using the bicinchoninic acid method and the LD50 in
mice (Table 1). The electrophoretic proﬁles of the venoms
were determined by the polyacrylamide electrophoresis
(Fig. 3a).
Previous studies have shown that the major venom in
the Crotalus species is crotoxin (Santoro et al., 1999).
Although some differences were noted, mainly in terms of
the electrophoretic mobility of the protein bands and their
intensity, the venoms were similar overall in the four Cro-
talus subspecies. The differences noted, usually in the
concentrations of particular components, correlated with
the ages of the snake donors at the time of venom collec-
tion as well to the particular ecological regions fromwhich
the specimens were collected.
3.2. Chromatographic isolation of PLA2 from the C. durissus
terriﬁcus venom
C. d. terriﬁcus crude venom (20.0 mg) was applied to
aMono QHR 5\5 column (Amershan Pharmacia Biotech AB,Table 1
Speciﬁc activity of antivenoms against C. d. terriﬁcus venom.
Antivenom Protein concentrationa Neutralizing
potencyb
Speciﬁc
activityc
IBU serum 93.10  22.96 131.60 0.082
IBU plasma 103.24  15.98 145.30 0.067
Exp. Group 1 105.80  3.10 416.70 0.023
Exp. Group 2 110.22  3.51 320.00 0.029
Exp. Group 3 116.19  6.05 403.00 0.022
a Protein concentration is expressed as mg/mL.
b Neutralization is expressed as Median Effective Dose (ED50), deﬁned
as the volume of antivenom (mL) required to reduce by 50% the mortality
of mice injected with 5 LD50.
c Speciﬁc activity value for each antivenom was calculated by using the
formula: SA ¼ (1000/mL corresponding to 1 ED50)/(mg/mL of protein
concentration).Uppsala, Sweden), which had been previously equilibrated
with pH 7.4 Tris buffer and eluted with a linear gradient of
NaCl (0.0–1.0 M) in pH 7.4 Tris buffer. The chromatography
resulted in 11 peaks (Fig. 2a). Peak 2 was represented by
only one 15 kDa protein band, whereas peaks 5 contained
a majority band of 15 kDa and the other of 30 kDa (Fig. 2b).
The activity of PLA2, as assayed on synthetic substrate L-a-
phosphatidylcholine, was detected only in peak 2 (data not
shown). Upon “dot blotting” using speciﬁc mouse anti-
crotoxin as the primary antibody, peak 5 reacted pos-
itively, indicating the presence of crotoxin (data not
shown).
3.3. Electrophorectic proﬁles of the different C. d. terriﬁcus
venoms
Equal samples of the C. d. terriﬁcus, C. d. collineatus, C. d.
cascavella and C. d. marajoensis venoms were treated with
SDS under reducing conditions and separated by poly-
acrylamide gel electrophoresis (upper gel, 5%; lower gel,
12.5%). Samples of puriﬁed crotoxin and PLA2 were run in
parallel. Fig. 3a shows strong similarities among the protein
proﬁles of all venoms. The presence of crotapotin, PLA2 and
conjugated crotoxin was indicated by the similar mobility
of the 10 kDa, 15 kDa and 30 kDa protein bands in the
samples with the isolated crotoxin and PLA2 controls that
were run in parallel. A band of 35 kDa, equivalent to
gyroxin, could be found in all the venom samples, although
not in the puriﬁed fractions.
3.4. Antivenom recognition of the antigenic components
present in the venom of four Crotalus species
Samples from the antivenom produced by the Instituto
Butantan and samples of the Crotalus venoms were elec-
trophoretically separated under reducing conditions on
polyacrylamide gel electrophoresis (upper gel, 5%; lower
gel, 12,5%). The protein bands were transferred to nitro-
cellulose membranes, treated with samples from the anti-
sera (diluted 1:5000) and exposed to rabbit IgG anti-horse
immunoglobulins as the second antibody. The recognition
patterns of the plasma and antivenom from the Instituto
Butantan were very similar, with the presence of bands
near 15 kDa and 30 kDa, corresponding to PLA2 and cro-
toxin, respectively (Fig. 3b and c). These proteins were
detected in all the venoms with great intensity. Bands at
50 kDa and 60 kDawere also found in the C. d. terriﬁcus, C. d.
collilineatus and C. d. cascavella venoms, and a 10 kDa band,
corresponding to crotapotin, was detected in the C. d. col-
lilineatus venom. In the plasma from Experimental Group 1,
bands at 15 kDa and 30 kDa were observed for all the
venoms, a 10 kDa band was observed for the C. d. terriﬁcus
and C. d. collilineatus venoms, and a 60 kDa band was
observed for the C. d. terriﬁcus venom (Fig. 3d). In the
plasma from Experimental Group 2, bands at 15 kDa and
30 kDa were observed in all the venoms, a band at 10 kDa
was observed for C. d. collilineatus venom, and bands at
50 kDa and 60 kDa were observed for the C. d. terriﬁcus
venom (Fig. 3e). In the plasma from Experimental Group 3,
only the 15 kDa band was observed for all the venoms
(Fig. 3f).
Fig. 2. Partial isolation of phospholipase 2 (PLA2) and crotoxin from C. d. terriﬁcus. a) Electrophoretic proﬁle of the crude C. d. terriﬁcus venom. Samples of the
venom (20.0 mg) were applied to a chromatography column packed with Mono Q HR 5/5 (Amershan Pharmacia Biotech AB, USA) after equilibration with Tris
25 mM, pH 7.4 buffer. Adsorbed proteins were eluted with a linear gradient of NaCl from 0 to 1.0 M. The samples were collected, the protein contents were
determined, and the presence of PLA2 quantiﬁed using a synthetic speciﬁc substrate. b) SDS-Page, upper gel 5%, lower gel 12.5%, stained with silver, conﬁrming
the majority presence of PLA2 in peak 2 and crotoxin in peak 5. In all, 10 mg of each sample was applied under reducing conditions.
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Equal samples from the antivenoms were diluted
(1:4.0  103 to 1:2.048  106) and assayed by ELISA. The
obtained O.D. values at 492 nm were plotted against the
corresponding serum dilutions, and dilutions giving O.D.
values of 0.2 were used to calculate the number of U-ELISA/
mL (Fig. 4). Antivenoms produced by the Instituto Butantan
obtained the highest titers against the C. d. terriﬁcus, C. d.
collilineatus, C. d. cascavella and C. d. marajoensis venoms.
Although no signiﬁcant difference could be observed, there
was a gap between the titers obtained against the crude
venoms and those obtained against the puriﬁed compo-
nents, suggesting that the high titers observed were related
to the recognition of components other than crotoxin and
PLA2. The titers obtained with plasma from Experimental
Group 1 were the lowest against all the antigens tested.
Plasma from Experimental Groups 2 and 3 showed high ti-
ters against the antigens tested. Of interest, no difference
could be found between the titers against crude venoms and
puriﬁed components, indicating that crotoxin andPLA2were
the components being recognized. Antibody activity against
the C. d. collilineatus, C. d. cascavella and C. d. marajoensis
venomswere foundwith all the antivenoms, although those
venomswere not used in the immunization schedules (with
the exception of C. d. collilineatus, which was used in the
Instituto Butantan’s immunization schedule).3.6. Antibody afﬁnity evaluation
The antibody afﬁnity for C. d. terriﬁcus crude venom,
crotoxin and PLA2 was evaluated by ELISAwith the addition
of KSCN in increasing concentrations as a chaotropic agent(Fig. 5). The antivenoms provided by the Instituto Butantan
showed the highest afﬁnity for the antigens used. The af-
ﬁnity scores from the three Experimental Groups were
lower, and there was no difference between them.
3.7. Neutralization of venom lethality
The lethal dose 50% (LD50) of C. d. terriﬁcus venoms was
calculated to be 1.2 mg per animal. Neutralizing activity was
assessed by injecting Swiss mice (18–20 g) with serial di-
lutions of antivenoms and 5 LD50 of venom, and neutrali-
zation was calculated by probit analysis. Results are
expressed as the volume of antivenom (mL) required to
neutralize 1 mg of venom (Fig. 6). Antivenom and plasma
provided by the Instituto Butantan showed a great neu-
tralizing capacity, with 2.18 mL and 2.42 mL required to
neutralize 1 mg of venom, respectively. Plasma from
Experimental Group 1 displayed a low neutralizing action,
with 6.15mL required to neutralize the venom. Plasma from
Experimental Group 2 showed the highest neutralization
capacity among the three Experimental Groups, although it
was still lower than the commercial antivenoms, requiring
3.80 mL to neutralize 1 mg of venom. Plasma from Exper-
imental Group 3 showed the lowest neutralizing capacity,
with 6.68 mL needed to neutralize the venom.
Using the in vivo neutralization data and the protein
concentration of the antivenoms, we were able to calculate
the speciﬁc activity against C. d. terriﬁcus venom (Table 1).
4. Discussion
The production of anti-snake venom antibodies to treat
victims bitten by venomous snakes was originally
Fig. 3. Electrophoretic proﬁle of different crotalic venoms and recognition by antivenoms as assessed by Western blotting (WB). a) SDS-Page, upper gel 5%, lower
gel: 12.5%, stained with silver. b) WB using detection by the Instituto Butantan serum. c) WB using detection by the Instituto Butantan plasma. d) WB using
detection by Experimental Group 1. e) WB using detection by Experimental Group 2. f) WB using detection by Experimental Group 3. In all, 10 mg of crude venom
or 2 mg of partially puriﬁed fractions was applied, under reducing conditions. Serum and plasma samples were diluted to 1:5000.
F.R. Guidolin et al. / Toxicon 66 (2013) 7–17 13developed in France at the Institute Pasteur (Calmette,1894)
and later developed and greatly expanded by Vital Brazil
(Brazil, 1901, 1903). Crude venoms and horses were the
immunogens and animals producing the antibodies,
respectively. Once the antivenom effectiveness was dem-
onstrated, the original procedure, although preserved in
essence, evolved as dictated by progress in ﬁelds such as
carbohydrate, lipid, and protein chemistry and basic
immunology. For example, the serum protein cleavage by
pepsin (Pope, 1936), with the clear objective of reducing the
amount of heterologous protein injection into the victims. In
addition to cleaving several non-antibody proteins, pepsin
cleaves the Fc region of the IgG molecule generating a sin-
gle, active, bivalent antigen-binding fragment, F(ab0)2
(Nisonoff et al., 1960). This fragment retains its original
antigen-binding capacity and loses its ability to activate the
complement system by the classical pathway, two prop-
erties that are absolutely required to neutralize venom
components in a victim’s circulation (WHO, 1981). Periodi-
cally, therefore, methods must be re-evaluated to take into
account the advances of relevant basic science disciplines.
In this work, Crotalus antivenom was selected for
improvement for several reasons. First, Crotalus venomscontain a limited number of relevant toxic components;
second, these components can be isolated as reasonably
homogeneous forms, and they can be titrated using trusted
techniques; third, animals can be immunized with sepa-
rated components; fourth, the envenoming symptoms are
quiet clear, allowing precise evaluation of both venom
lethality and antivenom neutralizing potency.
To improve the usual methodology, we ﬁrst charac-
terized six anti-Crotalus antivenom batches with respect to
speciﬁcity, potency, afﬁnity and speciﬁc activity. Although
the analyzed antivenoms exhibited the required overall
neutralization capabilities recommended by WHO (1981),
the afﬁnity and speciﬁc activity needed to be improved.
Antivenoms lacking these qualities are prone to induce
unavoidable adverse reactions by the presence of unnec-
essary contaminating protein and non-speciﬁc antibody.
Groups of horses were immunized according current
protocols using as antigen crude venoms or isolated cro-
toxin or PLA2. Blood samples were collected at strategic
times throughout the immunization, as dictated by the
antibody evolution during the immune response.
The antibody titer, neutralizing potency and afﬁnity
were evaluated by immunochemical and in vitro and in vivo
Fig. 4. Titration of plasma and sera from the Instituto Butantan and experimental plasma against venom from C. d. terriﬁcus, C. d. collilineatus, C. d. cascavella, C. d.
marajoensis, puriﬁed crotoxin and puriﬁed phospholipase A2. Plasma and sera were pooled within their respective groups and dilutions ranged from 1:4000 to
1:2,048,000. Titers are expressed as Units-ELISA/mL  106. Medians were compared by a one-way ANOVA followed by Dunn’s test, * P > 0.05. Data are rep-
resentative of two independent experiments.
Fig. 5. Afﬁnity determination of antivenoms for C. d. terriﬁcus venom, crotoxin and PLA2. Plasma and sera were pooled within their respective groups, and the
dilution was ﬁxed at 1:50,000. KSCN dilutions ranged from 0 M to 5 M in intervals of 0.5 M. The afﬁnity score is expressed as the concentration of KSCN necessary
to reduce to 50% the O.D. obtained with the controls (KSCN 0 M). Medians were compared by a one-way ANOVA followed by Dunn’s test, * P > 0.05. Data are
representative of two independent experiments.
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Fig. 6. Serum neutralization of C. d. terriﬁcus lethality in vivo. Swiss mice, 18–20 g, were injected intraperitoneally with mixtures of 5 DL50 of C. d. terriﬁcus venom
with antivenom dilutions (1:5, 1:10, 1:20 or 1:40). Plasma and sera were pooled within their respective groups. Deaths were recorded after 48 h, and ED50 was
calculated by probit analysis. Neutralization is expressed as volume of antivenom (mL) required to neutralize 1 mg of venom.
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crotoxin and PLA2 was an additional and important data
readout, and it was clearly successful.
The antivenoms provided by the Instituto Butantan
were able to recognize proteins present in the venoms of
the main Brazilian Crotalus snakes, and they showed high
titers against those venoms. Cross-reaction was expected,
as the venoms from those animals have a very similar
composition and biological activity (Santoro et al., 1999;
Rangel-Santos et al., 2004). This antivenom also provided
the highest neutralization of lethality in vivo, even though
titers against the most toxic components were relatively
low. The high-afﬁnity found for those components, how-
ever, might have acted to counterbalance the low titers and
therefore increase the neutralizing capacity. The anti-
venoms also recognized components in the other venoms,
as evidenced by both Western blotting and ELISA, which
corroborated our presupposition that the antivenoms cur-
rently produced have antibodies that bind to non-toxic
proteins and that are therefore irrelevant in the treatment.
In plasma from Experimental Group 1, obtained from
animals immunized with crude C. d. terriﬁcus venom,
500 mg/animal, we observed components in the different
crotalic venoms tested in a proﬁle similar to that of
Experimental Group 2. The use of a small quantity of an-
tigen might have directed the response toward the most
prevalent component in the venom, crotoxin. The plasma
yielded very low titers and neutralizing capacity. The
venom from C. d. terriﬁcus is known to possess immuno-
suppressive components (Cardoso and Mota, 1997) and, as
our results and the literature suggest, is not an effective
immunogen. The use of other venoms or proteins in addi-
tion to or as a substitute for C. d. terriﬁcus venom could
result in an antivenom of higher quality.
In plasma from Experimental Group 2, obtained from
animals immunized with crotoxin at 200 mg/animal, we
observed components present in the different crotalic
venoms with a speciﬁcity for conjugated crotoxin (30 kDa)
and PLA2 (15 kDa). There was no difference between titersagainst those components and titers against the crude
venoms, strongly indicating a great speciﬁcity in the
binding of the most toxic proteins. The plasma also showed
a high protective capacity in vivo, which was more effective
than that of the other Experimental Groups, and neutrali-
zation of crotalic venom by anti-crotoxin antibodies has
also been shown by other groups (Freitas et al., 1990;
Oshima-Franco et al., 1999; Beghini et al., 2004). The use of
crotoxin as an immunogen has to be carefully planned, as
crotoxin is themost toxic component present in the venom.
The use of low dosages, as shown here, and/or adjuvants
such as liposomes (Freitas and Frézard, 1997) could prevent
injuries and adverse reactions in the serum-producing
animals.
Plasma from Experimental Group 3, obtained from an-
imals immunized with phospholipase A2 (100 mg/animal),
showed a great speciﬁcity for that component, and we
observed almost exclusively that enzyme in the venom of
the different Crotalus snakes tested. The plasma also yiel-
ded the highest titers when compared to the other Exper-
imental Groups. However, the neutralizing capacity of this
plasma in vivo was the lowest. The dissociation of the
crotapotin/PLA2 complex plays a major role in the neu-
tralization of the crotalic venom (Choumet et al., 1996). Free
phospholipase, like that used for the immunization, might
present epitopes that differ from those presented by the
complexed phospholipase, resulting in antibodies that
were incapable of binding to the complexed enzyme and
therefore unable to promote the dissociation of the com-
plex. Antibodies against epitopes generated on the PLA2-
crotapotin complex interface, which were absent when the
animals were immunized with PLA2 alone, could be the
most effective neutralizing antibodies.
The immunization protocols tested were able to pro-
duce antibodies with high titers and cross-reactive capac-
ity, yet there was no increase in afﬁnity. Changes in the
schedules, with an increase in time between injections and
use of alternate adjuvants, are still open for testing and
could result in even better antivenoms.
F.R. Guidolin et al. / Toxicon 66 (2013) 7–1716This work resulted in the production of antibodies with
high titers and speciﬁcities against the most toxic compo-
nents of C. d. terriﬁcus venom. The obtained antibodies
were capable of cross-reacting with components present in
the venom of other Brazilian Crotalus. Our next goal is the
identiﬁcation of CDRs present in the hypervariable regions
of these antibodies with speciﬁcity to crotoxin, crotapotin
and PLA2. Variability of CDR1 and CDR2 is encoded by the
germline and further diversiﬁed by somatic mutationwhile
each one of CDR L3 and CDRH3 is somatically diversiﬁed by
rearrangement of the V segment with the (J) L or diversity
(D) H and JH segments, respectively (Wu and Kabat, 1970;
Alazari et al., 1988; Padlan, 1994). Recognition of individual
antigen (Ag) is mainly mediated by CDR H3 (Kabat andWu,
1972). The amino acid sequences of these regions will be
used to construct homologous peptides potentially capable
of recognizing toxin domains.
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